Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa randomized double-blind placebo-controlled dose-finding study of CZ130 capsules in nonalcoholic steatohepatitis with damp-heat accumulation syndrome
CTR20210871Phase 2Active
- Sponsor
- Nanjing Hongjing Pharmaceutical Technology
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CZ130 in metabolic dysfunction-associated steatohepatitis (MASH), metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Nanjing Hongjing Pharmaceutical Technology. Started May 2021; status: active.
02
Drugs
CZ130
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on CTR20210871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210871.